Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lin Shen

Showing results (1331-1340 of 1,553) with videos related to

Pageof 156
Sort By:
Radiology|February 1, 2022
Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized TrialKanglian Zheng, Xu Zhu, Shijie Fu, et al.
Gastrointestinal Endoscopy|September 20, 2020
Size of Lugol-unstained lesions as a predictor for risk of progression in premalignant lesions of the esophagusMengfei Liu, Ren Zhou, Chuanhai Guo, et al.
Brain : a Journal of Neurology|January 1, 2019
MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulationBing-Lin Zhu, Yan Long, Wei Luo, et al.
BMC Cancer|August 13, 2024
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trialJoon Oh Park, Yin-Hsun Feng, Wu-Chou Su, et al.
The Lancet. Gastroenterology & Hepatology|October 9, 2021
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trialRui-Hua Xu, Yanqiao Zhang, Hongming Pan, et al.
World Journal of Gastroenterology|August 6, 2008
Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer preventionGuo-Shuang Feng, Jun-Ling Ma, Benjamin C Y Wong, et al.
The Lancet. Oncology|November 2, 2013
Management of gastric cancer in Asia: resource-stratified guidelinesLin Shen, Yan-Shen Shan, Huang-Ming Hu, et al.
Nanoscale|December 16, 2015
Bridging the "green gap" of LEDs: giant light output enhancement and directional control of LEDs via embedded nano-void photonic crystalsYu-Lin Tsai, Che-Yu Liu, Chirenjeevi Krishnan, et al.
The Lancet. Oncology|April 18, 2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trialJean-Yves Blay, Lin Shen, Yoon-Koo Kang, et al.
Frontiers in Immunology|September 26, 2022
Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancersYanni Wang, Jianling Zou, Yun Li, et al.
Pageof 156

Showing results (1331-1340 of 1,553) with videos related to

Sort By:
Pageof 156
Radiology|February 1, 2022
Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized TrialKanglian Zheng, Xu Zhu, Shijie Fu, et al.
Gastrointestinal Endoscopy|September 20, 2020
Size of Lugol-unstained lesions as a predictor for risk of progression in premalignant lesions of the esophagusMengfei Liu, Ren Zhou, Chuanhai Guo, et al.
Brain : a Journal of Neurology|January 1, 2019
MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulationBing-Lin Zhu, Yan Long, Wei Luo, et al.
BMC Cancer|August 13, 2024
Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trialJoon Oh Park, Yin-Hsun Feng, Wu-Chou Su, et al.
The Lancet. Gastroenterology & Hepatology|October 9, 2021
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trialRui-Hua Xu, Yanqiao Zhang, Hongming Pan, et al.
World Journal of Gastroenterology|August 6, 2008
Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer preventionGuo-Shuang Feng, Jun-Ling Ma, Benjamin C Y Wong, et al.
The Lancet. Oncology|November 2, 2013
Management of gastric cancer in Asia: resource-stratified guidelinesLin Shen, Yan-Shen Shan, Huang-Ming Hu, et al.
Nanoscale|December 16, 2015
Bridging the "green gap" of LEDs: giant light output enhancement and directional control of LEDs via embedded nano-void photonic crystalsYu-Lin Tsai, Che-Yu Liu, Chirenjeevi Krishnan, et al.
The Lancet. Oncology|April 18, 2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trialJean-Yves Blay, Lin Shen, Yoon-Koo Kang, et al.
Frontiers in Immunology|September 26, 2022
Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancersYanni Wang, Jianling Zou, Yun Li, et al.
Pageof 156